Regensight srl has been granted by Lazio Innova SpA the contribution n. A0613-2023-077528 under the “CSR Competitive Repositioning” Notice, FESR Program 2021-2027 referred to in Det. n. G18823 of 28/12/2022 and granted with Det. n. G15206 of 16/11/2023. The subsidy is granted for activities related to the project entitled “Development of a theranostic platform for the correction of visual disorders”.
The project aims to introduce high technological and innovative products with the aim to improving current therapeutic strategies of keratoconus, a corneal disease that represents one of the primary causes of vision loss in young people globally and to create a revolutionary paradigm for the correction of low-grade myopia and presbyopia, the most frequent visual disorders that jointly afflict half of the world’s population.
The aim of the project is the validation of the theranostics platform for the treatment of the most frequent visual disorders in the world.
Regensight has completed the project SAL as of 30/06/2024. The project will be completed by 21/05/2025.
The Project was admitted and financed for the amount of the contribution granted (€ 375,556.92) and the total of Eligible Expenses (€ 721,009.30) indicated in the application prot. no. A0613-2023-077528. In 2024, Regensight srl received the contribution of € 300,445.54.
Regensight srl has been awarded the grant application prot. n. A0122-2020-35929 under the “PRE-SEED” public tender – POR FESR LAZIO 2014 – 2020.(www.europa.eu; e http://www.lazioinnova.it/bandi-post/pre-seed-sostegno-alla-creazione-al-consolidamento-startup-innovative-ad-alta-intensita-applicazione-conoscenza-alle-iniziative-spin-off-della-ricerca/)
This grant has been awarded for the activities related to the project entitled: “Development of a non-invasive surgical platform for the visual correction of keratoconus”.
The main purpose of the project is to develop a pre-series batch of ten UV-A medical devices to accelerate the clinical research activities for validating the theranostics paradigm for the treatment of keratoconus.
The realization of the project objectives will allow Regensight to seize the opportunity to accelerate its entry into the market and lay the foundations to become one of the main world players
committed to reducring the social burden of treatment of keratoconus.
The results will be presented as soon as they are available. The project started on December 3, 2020 and will end by December 2, 2021.
The maximum concession grant relating to the “Pre-seed” call is € 100,000.
Regensight srl has been awarded the grant application prot. n. A0122-2020-35929 under the “PRE-SEED” public tender – POR FESR LAZIO 2014 – 2020.(www.europa.eu; e http://www.lazioinnova.it/bandi-post/pre-seed-sostegno-alla-creazione-al-consolidamento-startup-innovative-ad-alta-intensita-applicazione-conoscenza-alle-iniziative-spin-off-della-ricerca/)
This grant has been awarded for the activities related to the project entitled: “Development of a non-invasive surgical platform for the visual correction of keratoconus”.
The main purpose of the project is to develop a pre-series batch of ten UV-A medical devices to accelerate the clinical research activities for validating the theranostics paradigm for the treatment of keratoconus.
The realization of the project objectives will allow Regensight to seize the opportunity to accelerate its entry into the market and lay the foundations to become one of the main world players
committed to reducring the social burden of treatment of keratoconus.
The results will be presented as soon as they are available. The project started on December 3, 2020 and will end by December 2, 2021.
The maximum concession grant relating to the “Pre-seed” call is € 100,000.